Biogen Inc. (BIIB): Price and Financial Metrics

Biogen Inc. (BIIB)

Today's Latest Price: $305.71 USD

28.05 (10.10%)

Updated Aug 7 12:00am

Add BIIB to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 344 in Biotech

See all "A" rated Strong Buy stocks

BIIB Stock Summary

  • With a market capitalization of $48,398,011,219, Biogen Inc has a greater market value than 95.94% of US stocks.
  • With a price/earnings ratio of 8.17, Biogen Inc P/E ratio is greater than that of about only 13.62% of stocks in our set with positive earnings.
  • The volatility of Biogen Inc's share price is greater than that of just 1.71% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Biogen Inc are MOSY, ICCC, CIEN, GRMN, and UTSI.
  • BIIB's SEC filings can be seen here. And to visit Biogen Inc's official web site, go to
BIIB Daily Price Range
BIIB 52-Week Price Range

BIIB Stock Price Chart Technical Analysis Charts

BIIB Price/Volume Stats

Current price $305.71 52-week high $374.99
Prev. close $277.66 52-week low $215.77
Day low $299.28 Volume 4,454,600
Day high $312.00 Avg. volume 1,840,563
50-day MA $280.03 Dividend yield N/A
200-day MA $296.89 Market Cap 48.40B

Biogen Inc. (BIIB) Company Bio

Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. The company was founded in 1985 and is based in Cambridge, Massachusetts.

BIIB Latest News Stream

Event/Time News Detail
Loading, please wait...

BIIB Latest Social Stream

Loading social stream, please wait...

View Full BIIB Social Stream

Latest BIIB News From Around the Web

Below are the latest news stories about Biogen Inc that investors may wish to consider to help them evaluate BIIB as an investment opportunity.

Biogen - Second Quarter Highlights World Of Opportunity

Biogen's (NASDAQ: BIIB) share price is mostly back to where it was when the company reported 2Q 2020 earnings a week ago. However, despite this, the company reported strong earnings with significant potential in major markets. The company's focus on new markets, along with the strength of its existing portfolio...

The Value Portfolio on Seeking Alpha | July 30, 2020

Top Health Care Stocks for August 2020

Health care, one of the largest and most complex sectors, is comprised of a broad range of companies that sell medical products and services. The health care sector includes companies that sell drugs, medical devices, and insurance, as well as hospitals and health care providers. Health care stocks, as represented by the Health Care Select Sector SPDR ETF (XLV), have outperformed the broader market, providing investors with a total return of 17.0% compared to the S&P 500's total return of 9.0% over the past 12 months. Several of these companies have received U.S. Emergency Use Authorization to develop either tests or treatments for COVID-19, sharply boosting their share price.

Yahoo | July 28, 2020

If You Invested $1,000 in Biogen During the Last Recession, This Is How Much You Would Have Today

You can also gather a much clearer picture of the strength of a stock based on how it does or doesn't perform during a global recession. If you own shares of Biogen (NASDAQ: BIIB) or are thinking about purchasing this stock, you might be curious about what your investment would look like now if you'd bought in during the 2008 recession. If you had bought $1,000 worth of Biogen back then, how much would you have today?

Yahoo | July 28, 2020

Stocks - Moderna, Apple Rise Premarket; Hasbro Falls

Yahoo | July 27, 2020

Here's Why Biogen Just Blew Its Q2 Earnings Out of the Water

Biogen (NASDAQ: BIIB) saw its stock jumped after the company released its second-quarter results on Thursday. The biotech beat analysts' earnings estimates for the fifth consecutive quarter with diluted earnings per share (EPS) based on generally accepted accounting principles (GAAP) increasing by 22% year over year. Biogen estimates that its GAAP diluted EPS will be between $32 and $34 rather than the prior estimated range of $29.50 to $31.50.

Yahoo | July 25, 2020

Read More 'BIIB' Stories Here

BIIB Price Returns

1-mo 9.62%
3-mo -4.40%
6-mo -7.85%
1-year 29.65%
3-year 7.77%
5-year 4.79%
YTD 3.03%
2019 -1.39%
2018 -5.54%
2017 21.96%
2016 -7.43%
2015 -9.75%

Continue Researching BIIB

Want to see what other sources are saying about Biogen Inc's financials and stock price? Try the links below:

Biogen Inc (BIIB) Stock Price | Nasdaq
Biogen Inc (BIIB) Stock Quote, History and News - Yahoo Finance
Biogen Inc (BIIB) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.906 seconds.